Barrier Effect of Normal Microbiota Against Clostridium difficile may be Influenced by Drugs Devoid of Antibiotic Activity

Article English OPEN
Barc, M.-C. ; Depitre, C. ; Corthier, G. ; Karjalainen, T. ; Bourlioux, P. (2011)
  • Publisher: Microbial Ecology in Health and Disease
  • Journal: Microbial Ecology in Health and Disease (issn: 1651-2235, eissn: 1651-2235)
  • Related identifiers: doi: 10.3402/mehd.v7i6.8307
  • Subject:
    mesheuropmc: digestive, oral, and skin physiology

Germ-free mice associated with human faecal microorganisms were used as a model of the microbial barrier against C. difficile. In this model, the production of toxins A and B by C. difficile was studied after oral treatment with phenothiazines (chlorpromazine and cyamemazine), methotrexate and an antibiotic (clindamycin). After 4 wks oral administration of chlorpromazine (10 mg/kg/day) and cyamemazine (35 mg/kg/day), neither the number of C. difficile nor the levels of toxin A and B in faecal pellets differed from those of untreated mice. C. difficile failed to establish in the intestine of mice colonised with human faecal microorganisms; neither toxin A nor B were detected in the faecal pellets of these animals. After treatment with clindamycin (10 d; 75 mg/kg/day) and methotrexate (4 wks; 250 mg/kg/day), the concentration of C. difficile in the faecal pellets was stable, and toxin B, but not toxin A, was detected. These results show that both clindamycin and methotrexate are able to disturb the intestinal barrier effect, whereas phenothiazines had little such effect.Keywords - Clostridium difficile, Barrier microbiota, Colonisation resistance.
  • References (36)
    36 references, page 1 of 4

    1. Barc MC, Depitre C, Gorthier G , Collignon A, Su WJ, Bourlioux P. (1992). Effects of antibiotics and other drugs on toxin production in Clostridium dzficile in vitro and in vivo. Antimicrobial Agents and Chemotherapy 6, 1332-1335.

    2. Bartlett JG. (1984). Treatment of antibiotic associated pseudomembranous colitis. Reviews of Infectious Diseases 6, 235-241.

    3. Bartlett JG. (1981). Antimicrobial agents implicated in Clostridium dificile toxin associated diarrhoea or colitis. Johns Hopkins Medical Journal 147, 4 9 .

    4. Boriello SP, Ketley JM, Mitchell TJ, Barclay FE, Welch AR, Price AB, Stephen NJ. (1987). Clostridiurn dificile: a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. Journal of Medical Microbiology 24, 53-64.

    5. Brunetto AL, Pearson ADJ, Craft AW, Pedler SJ. (1988). Clostridium dzficile in an oncology unit. Archives of Diseases of Children 63, 979-981.

    6. Church JM, Fazio VW. (1986). A role for colonic stasis in the pathogenesis of disease related to Clostridium dificile. Diseases of Colon and Rectum 29, 804809.

    7. Collignon A, Chaumard C, Vallet-Collomb I, Delepine N. (1988) Clostridiurn dificile chez des enfants et adolescents sous chimiothkapie anticanckreuse et antiinfectieuse; Possibilit6 d'une acquisition nosocomiale. Pathologie et Biologie 36, 755-758.

    8. Corthier G, Dubos F, Raibaud P. (1985). Modulation of cytotoxin production by Clostridium dificile in the intestinal tract of gnotobiotic mice inoculated with various human intestinal bacteria. Applied and E ~ v i r o n m e ~ M~aiclrobiology 49, 25CL252.

    9. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. (1991). Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium dificile toxin A. Infection and Immunity 59, 1192-1 195.

    10. Cudmore MA, Silva J, Fekety R, Liepmann MK, Kim KH. (1982). Clostridium dificile colitis associated with cancer chemotherapy. Archives of Internal Medicine 142, 333-335.

  • Similar Research Results (1)
  • Metrics
    views in OpenAIRE
    views in local repository
    downloads in local repository
Share - Bookmark